BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


SEARCH JOBS










 Company News
Agios Pharmaceuticals (AGIO) Announces Initiation Of A Phase 1/2 Clinical Trial Of AG-221 In Patients With Advanced Solid Tumors With An IDH2 Mutation 10/21/2014 7:42:29 AM
Agios Pharmaceuticals (AGIO) Smart Buy Ahead Of Cancer Data: Citi 10/16/2014 2:20:13 PM
Agios Pharmaceuticals (AGIO) Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221 10/15/2014 7:43:47 AM
Agios Pharmaceuticals (AGIO) To Webcast R&D Day On October 15, 2014 10/6/2014 7:39:24 AM
Agios Pharmaceuticals (AGIO) To Present Clinical Data From AG-120 Ongoing Phase 1 Study In Hematologic Malignancies At EORTC-NCI-American Association for Cancer Research 2014 9/26/2014 8:22:08 AM
Agios Pharmaceuticals (AGIO) To Present At The 2014 Leerink Partners Rare Disease Roundtable 9/24/2014 7:20:18 AM
Agios Pharmaceuticals (AGIO) Announces The U.S. FDA Grants Fast Track Designation To AG-221 For Treatment Of Patients With Acute Myelogenous Leukemia That Harbor An IDH2 Mutation 8/13/2014 7:27:33 AM
Agios Pharmaceuticals (AGIO) Reports Second Quarter 2014 Financial Results 8/7/2014 8:57:53 AM
Agios Pharmaceuticals (AGIO) To Webcast Conference Call Of Second Quarter 2014 Financial Results On August 7, 2014 7/28/2014 7:40:02 AM
New Agios Pharmaceuticals (AGIO) Clinical Data From Ongoing Phase 1 Trial Of AG-221 Continue To Show Complete And Durable Remissions In Patients With Difficult To Treat Hematologic Malignancies 6/16/2014 10:19:30 AM
12345678